NEW YORK, Dec. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals
(Nasdaq: KERX) today announced that the Independent Data Safety Monitoring
Committee (DSMC) responsible for monitoring Sulonex(TM) (sulodexide oral
gelcaps), the Company's lead drug candidate under development as a
treatment for diabetic nephropathy, recently met to evaluate the data from
the ongoing Phase 3 trial. Following a complete review of all available
safety and efficacy data, the DSMC found no cogent reason to recommend
alteration or termination of the Phase 3 trial. The DSMC raised no safety
concerns regarding Sulonex or the trial. As planned, no review was
conducted of the safety and efficacy data from the Phase 4 trial during
this meeting.

Prior to this most recent meeting, the DSMC had previously convened in
November 2006, in March 2007 and in August 2007 to review data from the
Phase 3 and Phase 4 studies. At each of these meetings the DSMC raised no
safety concerns.

On June 18, 2007, the Company announced the completion of patient
randomizations into the Phase 3 portion of the clinical registration
program. The Company anticipates that the last patient will complete the
active treatment period in mid-December 2007 and the two month
off-treatment period in mid-February 2008.

ABOUT THE SULONEX(TM) PHASE 3 and PHASE 4 CLINICAL PROGRAM

Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a
Special Protocol Assessment with the Food & Drug Administration. These
trials are being conducted by the Collaborative Study Group, the world's
largest standing renal clinical trials group.

The clinical plan to support an NDA approval for Sulonex(TM) under
Subpart H (accelerated approval), as agreed upon with the FDA under an SPA,
consists of: (i) a single Phase 3 trial in patients with microalbuminuria
based on the surrogate marker of regression of microalbuminuria as the
primary endpoint; (ii) supportive data from previously conducted clinical
studies; and (iii) substantial recruitment into our Phase 4 confirmatory
study that will measure clinical outcomes in patients with overt
nephropathy, or macroalbuminuria.

The Phase 3 clinical program is a multi-center, randomized,
double-blind, placebo-controlled study, comparing 200 mg daily of
Sulonex(TM) versus placebo, with a 1:1 randomization between the two arms.
The objective of this study is to determine the safety and efficacy of
sulodexide in the treatment of patients with type 2 diabetes and persistent
microalbuminuria, or diabetic nephropathy, despite being treated with a
maximum approved or tolerated dose of an angiotensin II receptor blocker
(ARB) or angiotensin-converting enzyme inhibitor (ACEi). The study is
designed for patients to be on treatment for six months, followed by two
months of evaluation off-treatment.

During the treatment and off-treatment evaluation period, all patients
in the study population are expected to continue to receive maximum
approved or tolerated doses of ACEis or ARBs. Patients who were not already
on maximum approved or tolerated doses of ACEis or ARBs for 120 days were
required to go into a run-in period prior to randomization of up to 120
days. This run-in period was designed to stabilize blood pressure and to
confirm persistent microalbuminuria while the patients are treated with
maximum approved or tolerated doses of ACEis or ARBs.

The primary endpoint for the Phase 3 clinical trial is "therapeutic
success" at 6 months, where therapeutic success is defined as (i)
conversion from microalbuminuria to normoalbuminuria, as measured by
albumin/creatinine ratio (ACR), with at least a 25% reduction in ACR
relative to baseline ACR, or (ii) a 50% reduction in ACR relative to
baseline ACR.

Concurrently with the Phase 3 clinical trial, the Company is continuing
enrollment into its Phase 4 clinical trial, which is a randomized, double-
blind, placebo-controlled study, also comparing 200 mg daily of Sulonex(TM)
versus placebo, with a 1:1 randomization between the two arms. The
objective of this Phase 4 study is to determine the efficacy of Sulonex(TM)
in reducing the rate of progression to End-stage renal disease and adverse
clinical sequelae in patients with type 2 diabetes and macroalbuminuria or
overt diabetic nephropathy, despite being treated with a maximum approved
or tolerated dose of an ARB. All patients in the Phase 4 study population
are expected to continue to receive maximum approved or tolerated doses of
ARBs during the course of the study. The Phase 4 study is designed to
enroll approximately 2,200 patients.

The Company has committed to the FDA, as a condition to the approval of
Sulonex(TM) based on the Phase 3 clinical trial under the guidelines of
accelerated approval, that the Phase 4 study would be substantially
enrolled at the time of the filing of the NDA for Sulonex.

ABOUT SULONEX(TM)

Sulonex (sulodexide oral gelcap) belongs to a proposed new class of
nephroprotective, or kidney protecting, drugs, known as the
glycosaminoglycans. A variety of members of this chemical family have been
shown to decrease pathological albumin excretion in diabetic nephropathy in
humans. Some of the members of this chemical family include the following
approved drugs: standard heparin, low molecular weight heparin and
danaparoid. These agents all require therapy by injection and are all
potent anticoagulants, which are blood thinners capable of inducing
bleeding. Sulonex, on the other hand, is given orally and, in this form,
has demonstrated little, if any, anticoagulant effects to date.

Keryx owns the exclusive rights to use Sulonex(TM) for the treatment of
diabetic nephropathy in North America, Japan and certain other markets
outside of Europe. Diabetic nephropathy is a long-term complication of
diabetes in which the kidneys are progressively damaged. Sulonex is a
glycosaminoglycan compound with structural similarities to the broad family
of marketed heparins and low molecular weight heparins. This drug has been
marketed in a number of European, Asian and South American countries for
many years by our licensor for certain cardiovascular conditions and has an
established safety profile at the doses used for such indications.
Additionally, it has been demonstrated in multiple clinical trials
conducted in Europe and the U.S., including two randomized, double-blind,
placebo-controlled Phase II studies, that Sulonex can reduce urinary
protein excretion in patients with diabetic nephropathy.

Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a
Special Protocol Assessment, or SPA, with the Food & Drug Administration,
or FDA. These trials are being conducted by the Collaborative Study Group,
or the CSG, the world's largest standing renal clinical trials group.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition,
development and commercialization of medically important, novel
pharmaceutical products for the treatment of life-threatening diseases,
including diabetes and cancer. Keryx's lead compound under development is
Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a
first-in-class, oral heparinoid compound for the treatment of diabetic
nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex
is in a pivotal Phase 3 and Phase 4 clinical program under a Special
Protocol Assessment with the Food & Drug Administration. Additionally,
Keryx is developing Zerenex(TM), an oral, iron- based compound that has the
capacity to bind phosphorous and form non- absorbable complexes. Zerenex is
currently in Phase 2 clinical development for the treatment of
hyperphosphatemia (elevated serum phosphorous levels) in patients with
end-stage renal disease. Keryx is also developing clinical- stage oncology
compounds, including KRX-0401 (perifosine), a novel, first-in- class, oral
modulator of Akt, a pathway associated with tumor survival and growth, and
other important signal transduction pathways. KRX-0401 is currently in
Phase 2 clinical development for multiple tumor types. Keryx also has an
active in-licensing and acquisition program designed to identify and
acquire additional drug candidates. Keryx is headquartered in New York
City.

Cautionary Statement

Some of the statements included in this press release, particularly
those anticipating future performance, future results from the Phase 3 and
Phase 4 clinical trials, timelines for the completion of the Sulonex(TM)
pivotal clinical trial program, including the Phase 3 and the Phase 4
clinical trials, the number of patients and clinical sites included in the
Phase 3 and Phase 4 clinical trials, expectations regarding FDA approval
and commercial launch of Sulonex(TM), market size estimates for
Sulonex(TM), growth and operating strategies, safety and/or efficacy of
Sulonex(TM), and similar matters, are forward-looking statements that
involve a number of risks and uncertainties. For those statements, we claim
the protection of the safe harbor for forward- looking statements contained
in the Private Securities Litigation Reform Act of 1995. Important factors
may cause our actual results to differ materially, including: our ability
to successfully complete the Sulonex(TM) pivotal clinical program on a
cost- effective basis; failure to meet the endpoints of the Phase 3 or
Phase 4 studies; and other risk factors identified from time to time in our
SEC reports, including, but not limited to, the report on Form 10- K for
the year ended December 31, 2006, and our quarterly report on Form 10-Q for
the quarter ended September 30, 2007. Any forward-looking statements set
forth in this news release speak only as of the date of this news release.
We do not intend to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof. This
press release and prior releases are available at http://www.keryx.com/.
The information in Keryx's website is not incorporated by reference into
this press release and is included as an inactive textual reference only.

(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...

(Date:10/7/2017)... Texas , Oct. 6, 2017 Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...

(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...

(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...

(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...